Skip to main content
Mijn bibliotheek
Shop
Nieuws Boeken Tijdschriften E-learning Web-tv Video Audio
Tips voor Mijn BSL
UITGEBREID ZOEKEN
Inloggen
Top
Gepubliceerd in:
Inleiding hoofdstuk lezen eerste hoofdstuk lezen

2021 | OriginalPaper | Hoofdstuk

8. Neurologische tumoren

Auteurs : Prof. dr. L. J. A. Stalpers, Drs. E. M. T. Dieleman, Prof. dr. W. P. Vandertop

Gepubliceerd in: Radiotherapie bij de oncologische patiënt

Uitgeverij: Bohn Stafleu van Loghum

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Samenvatting

– 1 Inleiding – 2 Gliomen – 3 Embryonale tumoren: medulloblastoom – 4 Meningeomen – 5 Hypofysetumoren – 6 Craniopharyngeoom – 7 Hersenmetastasen – 8 Spinale tumoren – 9 Wervelmetastasen. – Neuro-oncologie is de medische discipline die zich bezighoudt met de bestrijding van tumoren in het zenuwstelsel en de gevolgen daarvan. Het gaat om een groep zeer verschillende tumoren, die zich kunnen presenteren met een scala aan neurologische klachten en symptomen door prikkeling (zenuwpijn, epilepsie), uitval (verlammingen, gevoelsverlies), intracraniële drukverhoging (hoofdpijn, misselijkheid, braken) en psychische stoornissen (vermindering van het bewustzijn, verwardheid, geheugenverlies). Omdat hersentumoren zeldzaam zijn en het beeld niet altijd meteen duidelijk is, wordt de diagnose vaak pas na uitsluiting van goedaardige aandoeningen gesteld. Beeldvorming met MRI is meestal de belangrijkste stap naar een diagnose, en wordt gevolgd door neurochirurgie voor histologische bevestiging, directe symptoomverlichting en mogelijk genezing. Radiotherapie is geïndiceerd bij kwaadaardige tumoren (maligne gliomen), bij tumoren die niet of niet radicaal verwijderd kunnen worden (metastasen) en recidiverende tumoren (meningeomen). De neurologische gevolgen van een hersentumor zijn groot en vergen vaak langdurige zorg en ondersteuning.
vorige hoofdstuk Hoofd-halstumoren
volgende hoofdstuk Hematologische ziektebeelden
Literatuur
1.
Louis DN, Ohgaki H, Wiestler OD, et al. (Eds.). WHO classification of tumours of the central nervous system. 4th revised ed. Lyon: International Agency for Research on Cancer (IARC); 2016. p. 408.
2.
Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131:803–20.PubMedCrossRef
3.
4.
PALGA-Pathologisch Anatomisch Geautomatiseerd Archief. Openbare Databank. www.​palga.​nl, geraadpleegd op 29 oktober 2019.
5.
QRNS-Quality Registry Neuro Surgery. NVvN-Nederlandse Vereniging voor Neurochirurgie/SKN – Stichting Kwaliteitsbevordering Neurochirurgie, Utrecht. www.​qrns.​nl, geraadpleegd op 15 oktober 2019.
6.
7.
Jeene PM, De Vries KC, Van Nes JGH, Kwakman JJM, Wester G, Rozema T, Braam PM, Zindler JD, Koper P, Nuyttens JJ, Vos-Westerman HA, Schmeets I, Niël CGHJ, Hutschemaekers S, Van der Linden YM, Verhoeff JJC, Stalpers LJA. Survival after whole brain radiotherapy for brain metastases from lung cancer and breast cancer is poor in 6,325 Dutch patients treated between 2000 and 2014. Acta Oncol. 2018;57(5):637–43.PubMedCrossRef
8.
Michaud D, Savitz D, Mucci L. Chapter 24. Brain cancer. In: Adami HO, Hunter D, Lagiou P, Mucci L. Textbook of cancer epidemiology. 3rd ed. Oxford: Oxford University Press; 2018. pp. 587–608.
9.
Mertens AC, Liu Q, Neglia JP. Cause-specific late mortality among 5-year survivors of childhood cancer: the childhood cancer survivor study. J Natl Cancer Inst. 2008;100:1368–79.PubMedPubMedCentralCrossRef
10.
Armstrong GT. Long-term survivors of childhood central nervous system malignancies: the experience of the childhood cancer survivor study. Eur J Paediatr Neurol. 2010;14:298–303.PubMedPubMedCentralCrossRef
11.
Kok JL, Teepen JC, Van Leeuwen FE, Tissing WJE, Neggers SJCMM, Van der Pal HJ, Loonen JJ, Bresters D, Versluys B, Van den Heuvel-Eibrink MM, Van Dulmen-den Broeder E, Van der Heiden-van der Loo M, Aleman BMP, Daniels LA, Haasbeek CJA, Hoeben B, Janssens GO, Maduro JH, Oldenburger F, Van Rij C, Tersteeg RJHA, Hauptmann M; DCOG-LATER Study Group, Kremer LCM, Ronckers CM. Risk of benign meningioma after childhood cancer in the DCOG-LATER cohort: contributions of radiation dose, exposed cranial volume, and age. Neuro Oncol. 2019;21(3):392–403.
12.
13.
Velázquez Vega JE, Brat DJ. Incorporating advances in molecular pathology into brain tumor diagnostics. Adv Anat Pathol. 2018;25(3):143–71.PubMedCrossRef
14.
15.
De Witt Hamer PC, Robles SG, Zwinderman AH, Duffau H, Berger MS. Impact of intraoperative stimulation brain mapping on glioma surgery outcome: a meta-analysis. J Clin Oncol. 2012;30(20):2559–65.PubMedCrossRef
16.
17.
Brown TJ, Bota DA, Van Den Bent MJ, Brown PD, Maher E, Aregawi D, Liau LM, Buckner JC, Weller M, Berger MS, Glantz M. Management of low-grade glioma: a systematic review and meta-analysis. Neurooncol Pract. 2019;6(4):249–58.PubMed
18.
Taphoorn MJ, Schiphorst AK, Snoek FJ, Lindeboom J, Wolbers JG, Karim AB, Huijgens PC, Heimans JJ. Cognitive functions and quality of life in patients with low-grade gliomas: the impact of radiotherapy. Ann Neurol. 1994;36:48–54.PubMedCrossRef
19.
Van den Bent MJ, Afra D, De Witte O, Ben Hassel M, Schraub S, Hoang-Xuan K, Malmström PO, Collette L, Piérart M, Mirimanoff R, Karim AB; EORTC Radiotherapy and Brain Tumor Groups and the UK Medical Research Council. Long term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22,845 randomized trial. Lancet. 2005;366:985–90.
20.
Froma A, Mast M, Welleweerd J. Techniek in de radiotherapie. Houten: Bohn Stafleu van Loghum; 2020.CrossRef
21.
Stupp R, Mason WP, Van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005 Mar 10;352(10):987–96.
22.
Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997–1003.PubMedCrossRef
23.
Berghoff A, Van den Bent M. How i treat anaplastic glioma without 1p/19q codeletion. ESMO Open. 2019 Aug 20;4(Suppl 2):e000534.
24.
De Witt Hamer PC, Ho VKY, Zwinderman AH, Ackermans L, Ardon H, Boomstra S, Bouwknegt W, Van den Brink WA, Dirven CM, Van der Gaag NA, Van der Veer O, Idema AJS, Kloet A, Koopmans J, Ter Laan M, Verstegen MJT, Wagemakers M, Robe PAJT; Quality Registry Neuro Surgery glioblastoma working group from the Dutch Society of Neurosurgery. Between-hospital variation in mortality and survival after glioblastoma surgery in the Dutch quality registry for neuro surgery. J Neurooncol. 2019;144(2):313–23.
25.
Gately L, McLachlan SA, Dowling A, Philip J. Life beyond a diagnosis of glioblastoma: a systematic review of the literature. J Cancer Surviv. 2017;11(4):447–52.PubMedCrossRef
26.
Klein M. Treatment options and neurocognitive outcome in patients with diffuse low-grade glioma. J Neurosurg Sci. 2015;59(4):383–92.PubMed
27.
Buglione M, Ghirardelli P, Triggiani L, Pedretti S, Pasinetti N, De Bari B, Tonoli S, Borghetti P, Spiazzi L, Magrini SM. Radiotherapy for adult medulloblastoma: long term result from a single institution. A review of prognostic factors and why we do need a multi-institutional cooperative program. Rep Pract Oncol Radiother. 2015;20(4):284–91.
28.
Visser O. What is cancer? Epidemiology of benign CNS tumours. In: Stalpers L, Dirven C, Boogerd W, editors. Proceedings of the 66th oncology day on benign brain tumours. Amsterdam: The Netherlands Cancer Institute; 2008. p. 4.
29.
Stalpers LJA, Van Furth WR. Goedaardige tumoren. In: Kanker als chronische aandoening, onder redactie van: prof. dr. Meijboom-de Jong. Bijblijven. 2008;24(4):45–57.
30.
Stalpers LJ, Dieleman EM, Van Westing BR, Postma TJ, Van Furth WR. Diagnose en behandeling van hersentumoren. Ned Tijdschr Tandheelkd. 2009;116(4):202–7.PubMed
31.
Vernooij MW, Ikram MA, Tanghe HL, Vincent AJ, Hofman A, Krestin GP, Niessen WJ, Breteler MM, Van der Lugt A. Incidental findings on brain MRI in the general population. N Engl J Med. 2007;357(18):1821–8.PubMedCrossRef
32.
Van Alkemade H, De Leau M, Dieleman EM, Kardaun JW, Van Os R, Vandertop WP, Van Furth WR, Stalpers LJ. Impaired survival and long-term neurological problems in benign meningioma. Neuro Oncol. 2012;14(5):658–66.PubMedPubMedCentralCrossRef
33.
Van Nieuwenhuizen D, Klein M, Stalpers LJ, Leenstra S, Heimans JJ, Reijneveld JC. Differential effect of surgery and radiotherapy on neurocognitive functioning and health-related quality of life in WHO grade I meningioma patients. J Neurooncol. 2007 Sep;84(3):271–8.
34.
Dijkstra M, Van Nieuwenhuizen D, Stalpers LJ, Wumkes M, Waagemans M, Vandertop WP, Heimans JJ, Leenstra S, Dirven CM, Reijneveld JC, Klein M. Late neurocognitive sequelae in patients with WHO grade I meningioma. J Neurol Neurosurg Psychiatry. 2009;80(8):910–5.PubMedCrossRef
35.
Waagemans ML, Van Nieuwenhuizen D, Dijkstra M, Wumkes M, Dirven CM, Leenstra S, Reijneveld JC, Klein M, Stalpers LJ. Long-term impact of cognitive deficits and epilepsy on quality of life in patients with low-grade meningiomas. Neurosurg. 2011;69(1):72–8.CrossRef
36.
37.
Ghose A, Guha G, Kundu R, Tew J, Chaudhary R. CNS Hemangiopericytoma: a systematic review of 523 patients. Am J Clin Oncol. 2017;40(3):223–7.PubMedCrossRef
38.
Nishioka H, Inoshita N. New WHO classification of pituitary adenomas (4th ed.): assessment of pituitary transcription factors and the prognostic histological factors. Brain Tumor Pathol. 2018;35(2):57–61.
39.
Lo AC, Howard AF, Nichol A, Sidhu K, Abdulsatar F, Hasan H, Goddard K. Long-term outcomes and complications in patients with craniopharyngioma: the British Columbia cancer agency experience. Int J Radiat Oncol Biol Phys. 2014;88(5):1011–8.PubMedCrossRef
40.
Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990;322:494–500.PubMedCrossRef
41.
Vecht CJ, Haaxma-Reiche H, Noordijk EM, et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol. 1993;33:583–90.PubMedCrossRef
42.
Noordijk EM, Vecht CJ, Haaxma-Reiche H, et al. The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int J Radiat Oncol Biol Phys. 1994;29:711–7.PubMedCrossRef
43.
Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004;363:1665–72.PubMedCrossRef
44.
Muacevic A, Wowra B, Siefert A, Tonn JC, Steiger HJ, Kreth FW. Microsurgery plus whole brain irradiation versus Gamma Knife surgery alone for treatment of single metastases to the brain: a randomized controlled multicentre phase III trial. J Neurooncol. 2008;87:299–307.PubMedCrossRef
45.
Kondziolka D, Patel A, Lunsford LD, Kassam A, Flickinger JC. Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys. 1999;45:427–34.PubMedCrossRef
46.
Yamamoto M, Serizawa T, Shuto T, Akabane A, Higuchi Y, Kawagishi J, Yamanaka K, Sato Y, Jokura H, Yomo S, Nagano O, Kenai H, Moriki A, Suzuki S, Kida Y, Iwai Y, Hayashi M, Onishi H, Gondo M, Sato M, Akimitsu T, Kubo K, Kikuchi Y, Shibasaki T, Goto T, Takanashi M, Mori Y, Takakura K, Saeki N, Kunieda E, Aoyama H, Momoshima S, Tsuchiya K. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol. 2014;S1470–2045(14):70061.
47.
Chang EL, Wefel JS, Hess KR, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole brain irradiation: a randomized controlled trial. Lancet Oncol. 2009;10:1037–44.PubMedCrossRef
48.
Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus whole brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases. A randomized controlled trial. JAMA. 2006;295:2483–91.PubMedCrossRef
49.
Kocher M, Soffietti R, Abacioglu U, et al. Adjuvant whole brain radiotherapy versus observation after radiosurgery or surgical resection of 1–3 cerebral metastases: results of the EORTC 22952–26001 study. J Clin Oncol. 2011;29:134–41.PubMedCrossRef
50.
Soffietti R, Kocher M, Abacioglu UM, et al. A European organisation for research and treatment of cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. J Clin Oncol. 2013;31(1):65–72.PubMedCrossRef
51.
Horton J, Baxter DH, Olson KB. The management of metastases to the brain by irradiation and corticosteroids. Am J Roentgenol Radium Ther Nucl Med. 1971;111(2):334–6.PubMedCrossRef
52.
Mulvenna P, Nankivell M, Barton R, Faivre-Finn C, Wilson P, McColl E, Moore B, Brisbane I, Ardron D, Holt T, Morgan S, Lee C, Waite K, Bayman N, Pugh C, Sydes B, Stephens R, Parmar MK, Langley RE. Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial. Lancet. 2016;388(10055):2004–14.PubMedPubMedCentralCrossRef
53.
Nieder C, Norum J, Dalhaug A, Aandahl G, Pawinski A. Radiotherapy versus best supportive care in patients with brain metastases and adverse prognostic factors. Clin Exp Metastasis. 2013;30(6):723–9.PubMedCrossRef
54.
Slooff JL, Kernohan JW, MacCarty CS. Primary intramedullary tumors of the spinal cord and filum terminale. Philadelphia: Saunders; 1964.
55.
Vandertop WP, Van Wanroij JL, Rosenberg WWJ, Tulleken CAF. Resectie als behandeling van spinale intramedullaire tumoren. Ned Tijdschr Geneeskd. 1991;135:664–8.PubMed
56.
Spratt DE, Beeler WH, De Moraes FY, Rhines LD, Gemmete JJ, Chaudhary N, Shultz DB, Smith SR, Berlin A, Dahele M, Slotman BJ, Younge KC, Bilsky M, Park P, Szerlip NJ. An integrated multidisciplinary algorithm for the management of spinal metastases: an international spine oncology consortium report. Lancet Oncol. 2017;18(12):e720–30.PubMedCrossRef
57.
Patchell RA, Tibbs PA, Regine WF, Payne R, Saris S, Kryscio RJ, Mohiuddin M, Young B. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet. 2005;366(9486):643–8.PubMedCrossRef
58.
Rades D, Stalpers LJ, Veninga T, Schulte R, Hoskin PJ, Obralic N, Bajrovic A, Rudat V, Schwarz R, Hulshof MC, Poortmans P, Schild SE. Evaluation of five radiation schedules and prognostic factors for metastatic spinal cord compression. J Clin Oncol. 2005;23(15):3366–75.PubMedCrossRef
59.
Rades D, Veninga T, Stalpers LJ, Basic H, Hoskin PJ, Karstens JH, Schild SE, Dunst J. Improved posttreatment functional outcome is associated with better survival in patients irradiated for metastatic spinal cord compression. Int J Radiat Oncol Biol Phys. 2007;67(5):1506–9.PubMedCrossRef
Metagegevens
Titel
Neurologische tumoren
Auteurs
Prof. dr. L. J. A. Stalpers
Drs. E. M. T. Dieleman
Prof. dr. W. P. Vandertop
Copyright
2021
Uitgeverij
Bohn Stafleu van Loghum
Boek
Radiotherapie bij de oncologische patiënt

Print ISBN: 978-90-368-2611-2

Elektronisch ISBN: 978-90-368-2612-9

Copyright: 2021

DOI
https://doi.org/10.1007/16013_2020_27